Sin, India
Ta Yaya Hoton Ganewa Zai Ceci Rayuka a Yaƙin Myeloma da yawa?
Kuna son sanin yadda dabarar likita ke ceton rayukan marasa lafiya myeloma da yawa? Karanta shafinmu don ƙarin koyo game da wannan dabarar ceton rai! Mu juya shafin kan cutar kansa tare. Labarin begen ku ya fara anan. Jahannama..
anti-BCMA, BCMA CAR-T, chimeric antigen receptor T cell far, Sin, Immune thrombocytopenia, E.T.C
Anti-BCMA CAR T-Cell gwajin gwaji na asibiti don sake dawowa/refractory Immune thrombocytopenia (R/R ITP)
Maris 2023: Immune thrombocytopenia (ITP) cuta ce da ke haifar da sauƙi ko wuce gona da iri da zub da jini. Kusan kashi biyu cikin uku na marasa lafiya sun sami gafara bayan / lokacin jiyya na farko. Duk da haka, dayan part o..
fasahar binciken halittu, Mota-T Ciwon ƙwayar cuta, T-Cell CAR, CAR far, Sin, tara kudi, Oricell Therapeutics
Oricell yana haɓaka ƙarin $45M USD don faɗaɗa maganin CAR T-Cell zuwa Amurka
23 ga Maris, 2023: Na'urar rigakafin ciwon daji da farkon matakin da Shanghai Biotech Oricell ke samarwa sun sami ƙarin dala miliyan 45 a cikin tallafi, kamfanin ya sanar a ranar Talata. Bayan an nuna shi a AS..
Beijing, CARTITUDE-4, CARVYKTI, Sin, ciltacabtagene autoleucel, Gwajin gwaji, Labarin biotech, myeloma mai yawa, Shanghai
Legend Biotech Ya Sanar da Mataki na 3 CARTITUDE-4 Nazarin CARVYKTI®(ciltacabtagene autoleucel) Ya Gana Ƙarshen Ƙarshen Sa na Farko a cikin Jiyya na Marasa lafiya tare da Maimaitawa da Mai Rarraba Multiple Myeloma
JANUARY 27, 2023-Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), kamfani ne na fasahar kere-kere na duniya da ke haɓaka, kerawa da kuma tallata hanyoyin kwantar da hankali don magance cututtuka masu haɗari, ya sanar a yau cewa ..
Beijing, fasahar binciken halittu, Cell far, Maganin salula, Sin, Cilta-Cel, ciltacabtagene autoleucel, Labarin biotech
Legend Biotech ya ba da sanarwar Karɓar Sabuwar Aikace-aikacen Magunguna don Ciltacabtagene Autoleucel (Cilta-Cel) a China
SOMERSET, NJ — JANUARY 2, 2023— Kamfanin Legend Biotech (NASDAQ: LEGN) (Legend Biotech), kamfani ne na fasahar kere-kere na duniya da ke haɓaka, kerawa da kuma tallata hanyoyin kwantar da hankali don magance cututtukan da ke barazana ga rayuwa, ann.
Sin, Gwajin gwaji, carcinoma hepatocellular, JW Therapeutics, Shanghai
JW Therapeutics Ya Sanar da Fara Nazarin Asibiti na JWATM214 a cikin Marasa lafiya tare da Ciwon Ciwon Ciwon Hanta
SHANGHAI, CHINA, Fabrairu 28, 2023 - JW Therapeutics (HKEX: 2126), wani kamfani mai zaman kansa kuma mai haɓaka fasahar kere kere wanda ke mai da hankali kan haɓakawa, masana'antu da kasuwancin samfuran rigakafin ƙwayoyin cuta, ya sanar da init.
Americanungiyar Hematology ta Amurka, Karteyva, Sin, JW Therapeutics, relmacabtagene autoleucel
JW Therapeutics Yana Gabatar da Sabbin Bayanan Clinical akan Carteyva® a cikin Follicular Lymphoma da Mantle Cell Lymphoma a Taron Shekara-shekara na ASH na 64th
SHANGHAI, CHINA, Disamba 12, 2022 Wani kamfani mai zaman kansa kuma mai ƙirƙira na fasahar kere kere mai suna JW Therapeutics (HKEX: 2126) yana mai da hankali kan haɓakawa, ƙira, da siyar da samfuran rigakafin ƙwayoyin cuta. A taron jama'ar Amirka na 64.
Cell far, Sin, JW Therapeutics, Shanghai
JW Therapeutics Ya Sanar da Cewa Magungunan Immunotherapy Kwayoyinsa sun Yi Nasarar Amfani da Marasa lafiya 300
SHANGHAI, CHINA, Nuwamba 9, 2022 - JW Therapeutics (HKEX: 2126), wani kamfani mai zaman kansa kuma mai haɓaka fasahar kere kere wanda ke mai da hankali kan haɓakawa, masana'antu, da kasuwancin samfuran rigakafin ƙwayoyin cuta, ya sanar da cewa kamar yadda N..
2 saba'in bio, Sin, immunotherapy, JW Therapeutics, Partnership
JW Therapeutics da 2 saba'in bio sun Sanar da Haɗin gwiwar Dabarun don Haɓaka Bincike da Haɓaka Magunguna na tushen T-cell
SHANGHAI, CHINA and CAMBRIDGE, MASSACHUSETTS, US, October 27, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherap..
Sin, Enhertu, TA 2 tabbatacce
An amince da Enhertu a China don majinyata da ke da HER2-tabbataccen ciwon nono
Feb 2023: An amince da Enhertu (trastuzumab deruxtecan) daga AstraZeneca da Daiichi Sankyo a matsayin monotherapy don kula da manya marasa lafiya tare da ciwon daji na HER2 mai kyau wanda ba a iya ganewa ba ko metastatic.